Completed OBSERVATIONAL NCT00782366

Predictive Genetic Risk Assessment Trial (PGT)

Proof-of-Principle Trial of Communication to Patients Receiving Predictive Genetic Risk Assessment

Sponsor: Mayo Clinic

Conditions Atrial Fibrillation Breast Cancer Celiac Disease Colon Cancer Diabetes Type 2 Graves Disease Lung Cancer Myocardial Infarction Obesity Osteoarthritis Prostate Cancer

Interventions SNP analysis

Updated 6 times since 2017 Last updated: Apr 25, 2011 Started: Mar 31, 2008 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00782366, this observational or N/A phase trial focuses on Atrial Fibrillation and Breast Cancer and remains completed. Sponsored by Mayo Clinic, it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States